MAPK kinase inhibitor enhances cytotoxic effects induced by etoposide and ABT-737 in small cell lung cancer cells
碩士 === 國立交通大學 === 生物科技學系 === 103 === Small cell lung cancer (SCLC), exhibiting aggressive characteristics which differ from its counterpart non-small cell lung cancer (NSCLC), accounts for 13% of all lung cancer type worldwide. Chemotherapy coupling with radiotherapy remain the general management ap...
Main Author: | 蔡佩樺 |
---|---|
Other Authors: | 梁美智 |
Format: | Others |
Language: | en_US |
Published: |
2014
|
Online Access: | http://ndltd.ncl.edu.tw/handle/86090908559851142285 |
Similar Items
-
Pre-clinical evaluation of Bcl-2 inhibitor ABT-737 in small cell lung cancer
by: Micha, Dimitra
Published: (2009) -
ABT-737 synergizes with Bortezomib to kill melanoma cells
by: Steven N. Reuland, et al.
Published: (2012-02-01) -
ABT-737 Synergizes with Cisplatin Bypassing Aberration of Apoptotic Pathway in Non-small Cell Lung Cancer
by: Eun Young Kim, et al.
Published: (2017-04-01) -
ABT-737, Synergistically Enhances Daunorubicin-Mediated Apoptosis in Acute Myeloid Leukemia Cell Lines
by: Hassan Dariushnejad, et al.
Published: (2014-03-01) -
Melatonin Can Modulate the Effect of Navitoclax (ABT-737) in HL-60 Cells
by: Alexey Lomovsky, et al.
Published: (2020-11-01)